---
title: "Xolair (omalizumab) in allergic asthma: Access and coverage questions"
description: "Access and coverage questions on Xolair (omalizumab) in allergic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Access and billing and Patient support. Questions: What is the J-code (HCPCS) for Xolair? Which HCPCS modifiers (JW, JZ) apply to Xolair claims? What patient support program is there for Xolair? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xolair--allergic-asthma/access-and-coverage"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab) in allergic asthma: Access and coverage questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)

Access and coverage questions that apply to every indication of Xolair are on [Xolair (omalizumab), all indications: Access and coverage](https://www.evicenter.com/medical-information/xolair/access-and-coverage).

## Access and billing

<a id="xolair-j-code"></a>

### What is the J-code (HCPCS) for Xolair?

> “Drug: HCPCS
> J2357
> Injection, omalizumab, 5 mg*”

Source: [XOLAIR: Sample Coding: Moderate to Severe Persistent Allergic Asthma, page 1, captured 2026-11-13](https://www.xolairhcp.com/content/dam/gene/accesssolutions/pdfs/coding/XOLAIR-Billing-Coding-for-Moderate-to-Severe-Presistent-Allergic-Asthma.pdf#page=1)

> “Applies to all NDC codes for XOLAIR.”

Source: [XOLAIR: Sample Coding: Moderate to Severe Persistent Allergic Asthma, page 1, captured 2026-11-13](https://www.xolairhcp.com/content/dam/gene/accesssolutions/pdfs/coding/XOLAIR-Billing-Coding-for-Moderate-to-Severe-Presistent-Allergic-Asthma.pdf#page=1)

> “These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting 
> the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech and Novartis do not make any 
> representation or guarantee concerning reimbursement or coverage for any item or service.”

Source: [XOLAIR: Sample Coding: Moderate to Severe Persistent Allergic Asthma, page 1, captured 2026-11-13](https://www.xolairhcp.com/content/dam/gene/accesssolutions/pdfs/coding/XOLAIR-Billing-Coding-for-Moderate-to-Severe-Presistent-Allergic-Asthma.pdf#page=1)

Note: The quote is from the manufacturer's sample coding sheet for moderate to severe persistent allergic asthma, linked from the Helpful Resources for Your Practice page.

<a id="xolair-jw-jz-modifiers"></a>

### Which HCPCS modifiers (JW, JZ) apply to Xolair claims?

> “HCPCS: Modifier<sup>†</sup>
> JW
> Drug amount discarded/not administered to any patient
> JZ
> Zero drug amount discarded/not administered to any patient”

Source: [XOLAIR: Sample Coding: Moderate to Severe Persistent Allergic Asthma, page 1, captured 2026-11-13](https://www.xolairhcp.com/content/dam/gene/accesssolutions/pdfs/coding/XOLAIR-Billing-Coding-for-Moderate-to-Severe-Presistent-Allergic-Asthma.pdf#page=1)

> “The JW modifier is required on claims for all single-dose containers or single-use drugs when an amount is discarded. The JZ modifier is required to be used as of 
> July 1, 2023. For more information on the JW and JZ modifiers, visit CMS.gov.”

Source: [XOLAIR: Sample Coding: Moderate to Severe Persistent Allergic Asthma, page 1, captured 2026-11-13](https://www.xolairhcp.com/content/dam/gene/accesssolutions/pdfs/coding/XOLAIR-Billing-Coding-for-Moderate-to-Severe-Presistent-Allergic-Asthma.pdf#page=1)

Note: The quote is from the manufacturer's sample coding sheet for moderate to severe persistent allergic asthma, linked from the Helpful Resources for Your Practice page.

## Patient support

<a id="xolair-patient-support-program"></a>

### What patient support program is there for Xolair?

> “The Support For You Program is a network of resources that can help answer your patients’ questions about XOLAIR, drive them to appropriate financial assistance options, and help them begin and continue the treatment you have prescribed.”

Source: [XOLAIR: Patient Support Program | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/resources/patient-support-program.html#:~:text=The%20Support%20For%20You%20Program%20is,the%20treatment%20you%20have%20prescribed.)

> “When your patient provides information, they will receive communications highlighting XOLAIR patient resources through multiple channels, including
>
> Optional, virtual 1:1 education session with a Clinical Education Manager* for information about XOLAIR, which now includes a session dedicated to self-injection
>
> A Patient Treatment Guide that details what to expect with XOLAIR. Includes information about efficacy, safety, financial support, and other patient resources relative to XOLAIR treatment
>
> Updates to keep patients informed and on track with their treatment, including XOLAIR patient testimonies
>
> Overview of other financial assistance options and the XOLAIR Co-pay Program”

Source: [XOLAIR: Patient Support Program | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/resources/patient-support-program.html#:~:text=When%20your%20patient%20provides%20information%2C,and%20the%20XOLAIR%20Co%2Dpay%20Program)

> “This program is only available for patients prescribed XOLAIR for IgE-mediated food allergy, allergic asthma, and chronic spontaneous urticaria.”

Source: [XOLAIR: Patient Support Program | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/resources/patient-support-program.html#:~:text=This%20program%20is%20only%20available,asthma%2C%20and%20chronic%20spontaneous%20urticaria.)

## Related pages
- [Medical information: Xolair (omalizumab): Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)
- [Indication](https://www.evicenter.com/medical-information/xolair--allergic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xolair--allergic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/xolair--allergic-asthma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/xolair--allergic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xolair--allergic-asthma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xolair--allergic-asthma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xolair--allergic-asthma/dosing-and-administration)
